日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Drastic Response to Olaparib in a Patient With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA2 Alterations and Near-Threshold Tumor Mutational Burden

奥拉帕尼治疗对携带 BRCA2 突变且肿瘤突变负荷接近阈值的转移性去势抵抗性前列腺癌患者产生了显著疗效

Yokota, Kotaro; Kosaka, Takeo; Daimon, Tatsuaki; Fujiwara, Shinnosuke; Nakamura, Kohei; Nishihara, Hiroshi; Oya, Mototsugu

MUC1-C auto-regulatory complex with EBNA1 is responsible for latent Epstein-Barr virus-associated gastric cancer progression.

MUC1-C 与 EBNA1 的自调节复合物是潜伏性 Epstein-Barr 病毒相关胃癌进展的原因

Ozawa Hiroki, Wang Yin, Withers Henry G, Haratake Naoki, Nakashoji Ayako, Bhattacharya Atrayee, Fushimi Atsushi, Kikutake Chie, Yamanoi Kazuhiro, White Shaowen, Wang Keyi, Daimon Tatsuaki, Shigeta Keisuke, Fukuda Kazumasa, Kawakubo Hirofumi, Kitagawa Yuko, Long Mark D, Gewurz Benjamin E, Kufe Donald

MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy.

MUC1-C 在耐药性前列腺癌中的依赖性揭示了抗体药物偶联疗法的靶点

Shigeta Keisuke, Daimon Tatsuaki, Hongo Hiroshi, Ku Sheng-Yu, Ozawa Hiroki, Haratake Naoki, Fushimi Atsushi, Nakashoji Ayako, Bhattacharya Atrayee, Takamori Shinkichi, Kono Michihisa, Rokugo Masahiro, Baba Yuto, Kosaka Takeo, Oya Mototsugu, Jacobi Justine, Long Mark D, Beltran Himisha, Kufe Donald

Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification

一名携带 BRCA2 突变型神经内分泌前列腺癌和 MDM2 扩增的患者对铂类化疗反应显著。

Daimon, Tatsuaki; Kosaka, Takeo; Hongo, Hiroshi; Aimono, Eriko; Nakamura, Kohei; Mikami, Shuji; Nishihara, Hiroshi; Oya, Mototsugu

Splenic cord capillary hemangioma with non-islet cell tumor hypoglycemia: a case report

脾索毛细血管瘤伴非胰岛细胞瘤性低血糖症:病例报告

Daimon, Tatsuaki; Kosaka, Takeo; Horinaga, Minoru; Saito, Junichi; Ueyama, Yoshito; Matsuzaki, Shoji; Oya, Mototsugu